Neovascular AMD
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD (NCT04704921) | AbbVie | 2020-12-29 |
Track Neovascular AMD automatically
Every clearance here is in the API, with alerts when new ones post.